image credit: Adobe Stock

RoslinCT, Lykan Bioscience Granted MIA License for cGMP Manufacturing Facilities

March 30, 2023


RoslinCT and Lykan Bioscience, companies involved in contract development and manufacturing for cell therapies, have been granted a Manufacturer’s Authorization License (MIA) for commercial manufacturing of cell therapy products from the Medicines and Healthcare products Regulatory Agency (MHRA), following a successful inspection at their Edinburgh, UK facility.

Completed in late 2021, RoslinCT’s newest 1,600 square-meter state-of-the-art facility, located in Edinburgh’s BioQuarter, was designed to operate as a flexible and scalable manufacturing hub, housing five cGMP clean rooms and a dedicated training laboratory. The cGMP facility has been designed and purpose-built specifically to accommodate cell therapy manufacturing processes for both allogeneic and autologous therapies with or without genome editing requirements.

Read More on Contract Pharma